^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Glioblastoma
    Drug:perillyl alcohol (NEO100) (Apoptosis stimulant, RAS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

    Excerpt:
    ...- Phase 2a: Patient must have a confirmed IDH1 mutation reverse transcription polymerase chain reaction (rtPCR) or immunohistochemistry (unless continuing into the Phase 2a portion of the study from the Phase I portion of the study)....
    Trial ID:
    NCT02704858
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Neurooncol Adv
    Title:

    Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma

    Published date:
    02/12/2021
    Excerpt:
    A total of 12 patients with recurrent GBM were enrolled into Phase I of this trial. NEO100 was administered...Four patients (33%), all of them with isocitrate dehydrogenase 1 (IDH1)-mutant tumors, survived >24 months. Intranasal glioma therapy with NEO100 was well tolerated. It correlated with improved survival when compared to historical controls...
    DOI:
    10.1093/noajnl/vdab005
    Trial ID:
    NCT02704858